vs
Side-by-side financial comparison of Emergent BioSolutions Inc. (EBS) and EverCommerce Inc. (EVCM). Click either name above to swap in a different company.
EverCommerce Inc. is the larger business by last-quarter revenue ($151.2M vs $148.7M, roughly 1.0× Emergent BioSolutions Inc.). EverCommerce Inc. runs the higher net margin — 4.0% vs -36.7%, a 40.7% gap on every dollar of revenue. On growth, EverCommerce Inc. posted the faster year-over-year revenue change (5.2% vs -23.6%). Emergent BioSolutions Inc. produced more free cash flow last quarter ($73.8M vs $21.0M). Over the past eight quarters, EverCommerce Inc.'s revenue compounded faster (4.7% CAGR vs -29.6%).
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
EverCommerce Inc. is a leading provider of integrated SaaS solutions tailored for small and medium-sized service-based businesses, operating primarily across North America and select global markets. Its product suite covers business management, payment processing, customer engagement, and marketing tools, serving key segments including home services, health & wellness, and fitness industries.
EBS vs EVCM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $148.7M | $151.2M |
| Net Profit | $-54.6M | $6.0M |
| Gross Margin | 42.9% | — |
| Operating Margin | -18.8% | 8.8% |
| Net Margin | -36.7% | 4.0% |
| Revenue YoY | -23.6% | 5.2% |
| Net Profit YoY | -74.4% | 149.4% |
| EPS (diluted) | $-0.95 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.7M | $151.2M | ||
| Q3 25 | $231.1M | $147.5M | ||
| Q2 25 | $140.9M | $148.0M | ||
| Q1 25 | $222.2M | $142.3M | ||
| Q4 24 | $194.7M | $143.7M | ||
| Q3 24 | $293.8M | $140.1M | ||
| Q2 24 | $254.7M | $140.5M | ||
| Q1 24 | $300.4M | $137.9M |
| Q4 25 | $-54.6M | $6.0M | ||
| Q3 25 | $51.2M | $11.1M | ||
| Q2 25 | $-12.0M | $8.2M | ||
| Q1 25 | $68.0M | $-7.7M | ||
| Q4 24 | $-31.3M | $-12.2M | ||
| Q3 24 | $114.8M | $-9.2M | ||
| Q2 24 | $-283.1M | $-3.4M | ||
| Q1 24 | $9.0M | $-16.3M |
| Q4 25 | 42.9% | — | ||
| Q3 25 | 62.8% | — | ||
| Q2 25 | 52.5% | — | ||
| Q1 25 | 60.2% | — | ||
| Q4 24 | 39.4% | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | -18.8% | — | ||
| Q1 24 | 49.2% | — |
| Q4 25 | -18.8% | 8.8% | ||
| Q3 25 | 33.1% | 10.8% | ||
| Q2 25 | 1.1% | 10.7% | ||
| Q1 25 | 22.5% | 10.0% | ||
| Q4 24 | -4.9% | 8.8% | ||
| Q3 24 | 22.0% | 7.2% | ||
| Q2 24 | -79.9% | 5.5% | ||
| Q1 24 | 13.2% | -3.1% |
| Q4 25 | -36.7% | 4.0% | ||
| Q3 25 | 22.2% | 7.5% | ||
| Q2 25 | -8.5% | 5.5% | ||
| Q1 25 | 30.6% | -5.4% | ||
| Q4 24 | -16.1% | -8.5% | ||
| Q3 24 | 39.1% | -6.5% | ||
| Q2 24 | -111.2% | -2.4% | ||
| Q1 24 | 3.0% | -11.8% |
| Q4 25 | $-0.95 | $0.04 | ||
| Q3 25 | $0.91 | $0.06 | ||
| Q2 25 | $-0.22 | $0.04 | ||
| Q1 25 | $1.19 | $-0.04 | ||
| Q4 24 | $-0.45 | $-0.06 | ||
| Q3 24 | $2.06 | $-0.05 | ||
| Q2 24 | $-5.38 | $-0.02 | ||
| Q1 24 | $0.17 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $205.4M | $129.7M |
| Total DebtLower is stronger | $589.7M | $523.4M |
| Stockholders' EquityBook value | $522.6M | $716.9M |
| Total Assets | $1.3B | $1.4B |
| Debt / EquityLower = less leverage | 1.13× | 0.73× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $205.4M | $129.7M | ||
| Q3 25 | $245.5M | $106.9M | ||
| Q2 25 | $267.3M | $151.1M | ||
| Q1 25 | $149.1M | $148.4M | ||
| Q4 24 | $99.5M | $135.8M | ||
| Q3 24 | $149.9M | $101.6M | ||
| Q2 24 | $69.7M | $86.7M | ||
| Q1 24 | $78.5M | $90.0M |
| Q4 25 | $589.7M | $523.4M | ||
| Q3 25 | $693.1M | $524.6M | ||
| Q2 25 | $700.0M | $525.8M | ||
| Q1 25 | $700.0M | $526.9M | ||
| Q4 24 | $700.0M | $527.9M | ||
| Q3 24 | $700.8M | $529.0M | ||
| Q2 24 | $863.8M | $530.1M | ||
| Q1 24 | $909.2M | $531.1M |
| Q4 25 | $522.6M | $716.9M | ||
| Q3 25 | $582.5M | $728.5M | ||
| Q2 25 | $536.2M | $744.0M | ||
| Q1 25 | $552.7M | $739.6M | ||
| Q4 24 | $482.8M | $750.8M | ||
| Q3 24 | $508.4M | $770.7M | ||
| Q2 24 | $386.3M | $784.1M | ||
| Q1 24 | $663.9M | $800.7M |
| Q4 25 | $1.3B | $1.4B | ||
| Q3 25 | $1.5B | $1.4B | ||
| Q2 25 | $1.4B | $1.4B | ||
| Q1 25 | $1.4B | $1.4B | ||
| Q4 24 | $1.4B | $1.4B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.5B | ||
| Q1 24 | $1.8B | $1.5B |
| Q4 25 | 1.13× | 0.73× | ||
| Q3 25 | 1.19× | 0.72× | ||
| Q2 25 | 1.31× | 0.71× | ||
| Q1 25 | 1.27× | 0.71× | ||
| Q4 24 | 1.45× | 0.70× | ||
| Q3 24 | 1.38× | 0.69× | ||
| Q2 24 | 2.24× | 0.68× | ||
| Q1 24 | 1.37× | 0.66× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $77.7M | $21.3M |
| Free Cash FlowOCF − Capex | $73.8M | $21.0M |
| FCF MarginFCF / Revenue | 49.6% | 13.9% |
| Capex IntensityCapex / Revenue | 2.6% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 3.52× |
| TTM Free Cash FlowTrailing 4 quarters | $156.8M | $109.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.7M | $21.3M | ||
| Q3 25 | $-2.3M | $32.5M | ||
| Q2 25 | $106.4M | $27.0M | ||
| Q1 25 | $-11.2M | $30.7M | ||
| Q4 24 | $-79.9M | $48.4M | ||
| Q3 24 | $153.7M | $27.5M | ||
| Q2 24 | $47.5M | $23.9M | ||
| Q1 24 | $-62.6M | $13.3M |
| Q4 25 | $73.8M | $21.0M | ||
| Q3 25 | $-5.7M | $31.6M | ||
| Q2 25 | $103.5M | $26.5M | ||
| Q1 25 | $-14.8M | $30.2M | ||
| Q4 24 | $-81.6M | $48.2M | ||
| Q3 24 | $147.9M | $27.4M | ||
| Q2 24 | $42.9M | $23.3M | ||
| Q1 24 | $-73.4M | $12.9M |
| Q4 25 | 49.6% | 13.9% | ||
| Q3 25 | -2.5% | 21.4% | ||
| Q2 25 | 73.5% | 17.9% | ||
| Q1 25 | -6.7% | 21.2% | ||
| Q4 24 | -41.9% | 33.5% | ||
| Q3 24 | 50.3% | 19.5% | ||
| Q2 24 | 16.8% | 16.6% | ||
| Q1 24 | -24.4% | 9.4% |
| Q4 25 | 2.6% | 0.2% | ||
| Q3 25 | 1.5% | 0.6% | ||
| Q2 25 | 2.1% | 0.3% | ||
| Q1 25 | 1.6% | 0.3% | ||
| Q4 24 | 0.9% | 0.2% | ||
| Q3 24 | 2.0% | 0.1% | ||
| Q2 24 | 1.8% | 0.5% | ||
| Q1 24 | 3.6% | 0.3% |
| Q4 25 | — | 3.52× | ||
| Q3 25 | -0.04× | 2.93× | ||
| Q2 25 | — | 3.31× | ||
| Q1 25 | -0.16× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -6.96× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
EVCM
| Transferred Over Time | $146.4M | 97% |
| Transferred At Point In Time | $4.8M | 3% |
